Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Chemoimmunotherapy | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | Feb 25, 2019 |
| PCV Regimen | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | 2013-02 |
| Taxane Compound | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Mar 9, 2027 |
| Buparlisib | Phase 3 | Phase 3 | 0 | 0 | 3 | 72 | 0 | — | — | 2008-11 |
| Enzastaurin | Phase 3 | Phase 3 | 0 | 0 | 4 | 48 | 0 | — | — | 2002-06 |
| Perifosine | Phase 3 | Phase 3 | 0 | 0 | 2 | 41 | 0 | — | — | 1999-08 |
| Dovitinib | Phase 3 | Phase 3 | 0 | 0 | 2 | 35 | 0 | — | — | 2011-03 |
| Tanespimycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 35 | 0 | — | — | 1998-08 |
| Ridaforolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 33 | 0 | — | — | 2003-04 |
| Vatalanib | Phase 3 | Phase 3 | 0 | 0 | 2 | 25 | 0 | — | — | 2003-01 |
| Volasertib | Phase 3 | Phase 3 | 0 | 0 | 1 | 22 | 0 | — | — | Nov 4, 2005 |
| Motesanib | Phase 3 | Phase 3 | 0 | 0 | 2 | 21 | 0 | — | — | 2003-07 |
| Linsitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 20 | 0 | — | — | Jun 18, 2007 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 13 | 18 | 0 | — | — | 2004-10 |
| Poziotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 18 | 0 | — | — | 2009-11 |
| Crenolanib | Phase 3 | Phase 3 | 0 | 0 | 4 | 17 | 0 | — | — | 2005-12 |
| Linifanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 17 | 0 | — | — | 2007-06 |
| Onartuzumab | Phase 3 | Phase 3 | 0 | 0 | 5 | 17 | 0 | — | — | 2007-08 |
| Rovalpituzumab Tesirine | Phase 3 | Phase 3 | 0 | 0 | 3 | 13 | 0 | — | — | 2013-07 |
| Iniparib | Phase 3 | Phase 3 | 0 | 0 | 2 | 12 | 0 | — | — | 2007-10 |
| Lucitanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 12 | 0 | — | — | 2010-07 |
| Rigosertib | Phase 3 | Phase 3 | 0 | 0 | 1 | 12 | 0 | — | — | 2006-06 |
| Rilotumumab | Phase 3 | Phase 3 | 0 | 0 | 3 | 12 | 0 | — | — | Oct 27, 2008 |
| Futuximab/Modotuximab Mixture | Phase 3 | Phase 3 | 0 | 0 | 2 | 11 | 0 | — | — | 2010-03 |
| Patidegib | Phase 3 | Phase 3 | 0 | 0 | 3 | 9 | 0 | — | — | 2008-09 |
| Lestaurtinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2003-08 |
| Naquotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | Jan 23, 2014 |
| Picoplatin | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2000-11 |
| Patritumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2010-09 |
| Pixantrone | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2001-12 |
| Rociletinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | Mar 27, 2012 |
| HDAC Inhibitor REC-2282 | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | May 4, 2010 |
| Radioactive Iodine | Phase 3 | Phase 3 | 0 | 0 | 2 | 2 | 0 | — | — | 2000-01 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Jun 7, 2023 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Jun 1, 2019 |
| FAC Regimen | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2011-11 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.